Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT05740943 2026-01-20

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Phase 2 Active not recruiting

48 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07083687 2025-07-24

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

Phase 2 Not yet recruiting

21 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06876675 2025-03-14

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Enrolling by invitation

167 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Hyperlipidemias

NCT06690541 2024-11-15

COMLORLA

Not yet recruiting

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

6,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT06282874 2024-02-28

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Phase 4 Not yet recruiting

50 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT05167500 2023-03-30

LORLAPULM

Completed

118 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasm Metastasis

NCT03439215 2021-07-19

PFROST

Phase 2 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02927340 2021-03-09

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Phase 2 Unknown

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

COMLORLA

PIKACHU

ATPase

EROS

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

LORLAPULM

PFROST

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions